{"filing":{"accession_number":"0001193125-26-389308","cik":"0001817241","ticker":"ARTV","company_name":"Artiva Biotherapeutics, Inc.","form":"8-K","filing_date":"2026-09-11","report_date":"2026-09-08","primary_document":"artv-20260908.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1817241/000119312526389308/artv-20260908.htm"},"events":[{"id":32956,"run_id":30298,"accession_number":"0001193125-26-389308","anchor_item_number":"5.07","event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"summary":"Artiva Biotherapeutics held its Annual Meeting on September 11, 2026, with shareholders voting on three proposals: election of Class II directors (Brian Daniels and Laura Stoppel), ratification of KPMG LLP as independent auditor, and approval of an amendment to the 2024 Equity Incentive Plan increasing authorized shares by 5,097,095. All three proposals passed with substantial majorities.","company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","filing_date":"2026-09-11","form":"8-K","submitted_at":null,"items":[{"id":36259,"accession_number":"0001193125-26-389308","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports stockholder approval of an amendment to the 2024 Equity Incentive Plan that increases authorized shares by 5,097,095 and modifies the calculation of automatic share reserve increases. This is a compensatory arrangement amendment affecting equity grants and incentive compensation, which falls squarely within Item 5.02(e) and the exec_compensation category. The material increase in share authorization and modification of plan mechanics would affect investor assessment of dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:22:48.846614+00:00","company_name":"","ticker":null,"filing_date":""},{"id":36260,"accession_number":"0001193125-26-389308","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Artiva's Annual Meeting held on September 11, 2026. The filing reports voting outcomes on three proposals: election of Class II directors (Brian Daniels and Laura Stoppel), ratification of KPMG LLP as independent auditor, and approval of an amendment to the 2024 Equity Incentive Plan increasing authorized shares by 5,097,095. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition, audit oversight, and equity dilution authorization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:22:48.846614+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":36259,"accession_number":"0001193125-26-389308","item_number":"5.02","item_title":null,"event_type":"exec_compensation","event_domain":"governance","is_material":true,"confidence":0.92,"reasoning":"The disclosure reports stockholder approval of an amendment to the 2024 Equity Incentive Plan that increases authorized shares by 5,097,095 and modifies the calculation of automatic share reserve increases. This is a compensatory arrangement amendment affecting equity grants and incentive compensation, which falls squarely within Item 5.02(e) and the exec_compensation category. The material increase in share authorization and modification of plan mechanics would affect investor assessment of dilution and executive compensation capacity.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:22:48.846614+00:00","company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","filing_date":"2026-09-11"},{"id":36260,"accession_number":"0001193125-26-389308","item_number":"5.07","item_title":null,"event_type":"shareholder_vote_results","event_domain":"governance","is_material":true,"confidence":0.98,"reasoning":"This is a classic Item 5.07 disclosure of shareholder vote results from Artiva's Annual Meeting held on September 11, 2026. The filing reports voting outcomes on three proposals: election of Class II directors (Brian Daniels and Laura Stoppel), ratification of KPMG LLP as independent auditor, and approval of an amendment to the 2024 Equity Incentive Plan increasing authorized shares by 5,097,095. All three proposals passed with substantial majorities, making this a material governance event that affects investor understanding of board composition, audit oversight, and equity dilution authorization.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-09-11T20:22:48.846614+00:00","company_name":"Artiva Biotherapeutics, Inc.","ticker":"ARTV","filing_date":"2026-09-11"}]}